Semaglutide and Biological Aging in Adults with HIV
Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging.
Semaglutide, the active ingredient in Ozempic and Wegovy, has been studied for its potential effects on biological aging in adults with HIV. This study provides the first clinical evidence that semaglutide may influence human aging. The researchers examined biological aging markers in adults with HIV who received semaglutide treatment. The results showed that semaglutide slowed biological aging markers in these individuals. However, the study's findings are limited by the small sample size and the need for larger, more comprehensive studies to confirm these results. The study's authors emphasize that the findings should not be interpreted as a guarantee of anti-aging effects or as a recommendation for using semaglutide for this purpose. Further research is necessary to fully understand the potential effects of semaglutide on biological aging in adults with HIV. The study's results highlight the importance of continued investigation into the potential therapeutic applications of semaglutide in this population.